Oncgnostics GmbH

As a biotechnology company, we at oncgnostics GmbH have been working on the diagnosis of cancer on a molecular biological basis since 2012. Our cancer tests are used in early cancer detection and diagnosis.Our first product, GynTect®, was developed with the aim of improving the early detection of cervical cancer. The molecular biological test for cervical cancer has been on the market since 2015 and exemplifies the technology we specialise in as a biotech company: Highly informative biomarkers patented by oncgnostics GmbH form the core of the company. Experienced scientists work together on innovative cancer diagnostics of the future. As a spin-off of the University Women’s Hospital Jena, oncgnostics GmbH with its research and development team works with international partners on various pipeline projects.